Tomohiro Anzai
Direktor/Vorstandsmitglied bei Modulus Discovery, Inc.
Profil
Tomohiro Anzai is currently the Director at AccuRna, Inc., the Outside Director at Braizon Therapeutics, Inc., the Director at Modulus Discovery, Inc., the Outside Director at PuREC KK, and the Representative partner at Fast Track Initiative, Inc. He previously worked as the Director at Modalis Therapeutics Corp.
Aktive Positionen von Tomohiro Anzai
| Unternehmen | Position | Beginn |
|---|---|---|
Fast Track Initiative, Inc.
 Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States. | Private Equity Investor | 04.03.2011 |
AccuRna, Inc.
 AccuRna, Inc. BiotechnologyHealth Technology AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | - |
Modulus Discovery, Inc.
 Modulus Discovery, Inc. BiotechnologyHealth Technology Modulus Discovery, Inc. preclinical stage drug Discovery Company. It is focused on rapid design and generation of small molecule clinical candidates for disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The company was founded by Shun Roy Kimura And Kazuki Ohno and is headquartered in Minato-ku, Japan. | Direktor/Vorstandsmitglied | - |
Braizon Therapeutics, Inc.
 Braizon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Braizon Therapeutics, Inc. is a Japanese company that engages in researching and developing drugs. The company was founded in 2015 by Mariko Tosu. The CEO is Bunichi Wanibuchi. | Direktor/Vorstandsmitglied | - |
PuREC KK
 PuREC KK BiotechnologyHealth Technology PuREC KK is a company based in Japan that aims to revolutionize the future of regenerative medicine by developing a high-purity mesenchymal stem cell culture technology called REC (Rapidly Expanding Cell). REC has approximately 1000 times more pharmacological efficacy in terms of proliferation and differentiation compared to normal mesenchymal stem cells, making it effective in treating a wide range of diseases. The Japanese company was founded in 2016 by Shotai Kobayashi. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tomohiro Anzai
| Unternehmen | Position | Ende |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States. | Finance |
AccuRna, Inc.
AccuRna, Inc. BiotechnologyHealth Technology AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan. | Health Technology |
Braizon Therapeutics, Inc.
Braizon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Braizon Therapeutics, Inc. is a Japanese company that engages in researching and developing drugs. The company was founded in 2015 by Mariko Tosu. The CEO is Bunichi Wanibuchi. | Commercial Services |
Modulus Discovery, Inc.
Modulus Discovery, Inc. BiotechnologyHealth Technology Modulus Discovery, Inc. preclinical stage drug Discovery Company. It is focused on rapid design and generation of small molecule clinical candidates for disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The company was founded by Shun Roy Kimura And Kazuki Ohno and is headquartered in Minato-ku, Japan. | Health Technology |
PuREC KK
PuREC KK BiotechnologyHealth Technology PuREC KK is a company based in Japan that aims to revolutionize the future of regenerative medicine by developing a high-purity mesenchymal stem cell culture technology called REC (Rapidly Expanding Cell). REC has approximately 1000 times more pharmacological efficacy in terms of proliferation and differentiation compared to normal mesenchymal stem cells, making it effective in treating a wide range of diseases. The Japanese company was founded in 2016 by Shotai Kobayashi. | Health Technology |
